2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Gene Editing, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Workforce, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, GVD, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Research, Fundamental Science, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6130 Estimating the maximum justifiable acquisition price of gene therapy for sickle cell disease in Nigeria: A cost-effectiveness analysis

Ishaan Vaswani, MS, BA, Dick Nchang, BA2, Mona Malone, MS3, Krystine Nhi Vuong, BA4, George Morgan, MSc5, Nowah Afangbedji, PhD6, Matthew Hebden Porteus, MD, PhD7
1 Stanford University, Stanford, United States, Stanford University, Stanford, United States
2 Stanford University, Stanford, United States
3 Stanford University, Stanford, United States
4 Stanford University, Stanford, United States
5 DHT.health, Clitheroe, United Kingdom, Lancaster University, Lancaster, United Kingdom
6 Stanford University, Stanford, United States
7 Stanford University, Stanford, United States

Introduction:

Sickle Cell Disease (SCD) is a major cause of morbidity and premature mortality in sub-Saharan Africa, placing a substantial clinical and economic burden on Lower-to Middle Income Countries (LMICs). Hydroxyurea (HU) is the standard of care in many settings with access to curative options limited. Gene therapy (GTx) offers the potential for durable remission, but associated with a substantial upfront cost. We evaluated the cost-effectiveness and maximum justifiable acquisition price of a one-time GTx vs. lifelong course of HU for SCD using a decision-analytic model adapted to the Nigerian healthcare setting.

Methods:

The Nigeria base case used separate three-State Markov models for HU (Mild, Severe, Dead) and GTx (Remission, Sick, Dead), with monthly cycles that run over a 55-year horizon from age 12. Patients receiving GTx entered the remission or sick health state according to response rates observed in the pivotal Casgevy trial. Mortality incorporated Nigeria-specific life tables with excess SCD mortality. Outcomes were measured as Quality Adjusted Life Years (QALYs). Costs (2024 USD) were estimated from a modified societal perspective, incorporating direct and indirect medical costs, while productivity losses were explored in sensitivity analyses. Costs and outcomes were discounted at 3% annually, with 0% and 5% explored in sensitivity analysis. As a Nigerian GTx acquisition price is unknown, the primary outcome is a maximum justifiable acquisition price (c*) at willingness-to-pay-thresholds of 1x and 3x GDP per capita, alongside a Nigeria-specific health opportunity cost (HOC) threshold. Probabilistic (5,000 simulations), one-way sensitivity and scenario analyses assessed parameter uncertainty.

Results:

GTx yielded 24.0 QALYs versus 12.9 for HU (Δ=11.1 QALYs), with discounted costs of $208,387 versus $22,863, resulting in an ICER of $16,725/QALY. The maximum justifiable acquisition price (c*) was $38,812 at the 1x GDP per capita threshold, and $85,655 at 3x GDP per captia, and $16,949 using the HOC threshold. Probabilistic analysis estimated a mean c* of $38,075 (95% CI: $26,537–$49,139). Compared with the only published LMIC delivery cost estimate (Uganda’s $40,205 drug +$8,604 administration cost = $48,809), Nigeria’s c* fell short by $10,607 at the 1x GDP threshold but exceeded delivery costs at the 3x GDP threshold.  Across all durability scenarios, c* remained positive declining to $24,535 assuming a 2%/year loss of response and ranged from $27,688-$42,795 across remission follow-up scenarios. When remission utility was assumed to equal to the mild disease state, the incremental benefit remained substantial (ΔQALYs was 8.605), indicating that gains were primarily driven by improved survival, from GTx, and avoidance of severe disease rather than differences in utility value.

Conclusions:

GTx delivers substantial health gains over HU for individuals with SCD in Nigeria. Estimating a country-specific maximum justifiable acquisition price provides an evidence-based target for value-based pricing. At the 1× GDP per capita threshold, the remaining affordability gap is $10,607, suggesting that curative therapy may be considerably closer to economic viability in LMICs than previously recognized.

 

 

 

 

 

Ishaan Vaswani, MS, BA: No relevant conflicts of interest to declare.